Reported Earnings • Nov 17
Third quarter 2024 earnings released: EPS: RON0.085 (vs RON0.074 in 3Q 2023) Third quarter 2024 results: EPS: RON0.085 (up from RON0.074 in 3Q 2023). Revenue: RON273.7m (up 17% from 3Q 2023). Net income: RON59.0m (up 14% from 3Q 2023). Profit margin: 22% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. New Risk • Nov 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Sep 03
Second quarter 2024 earnings released: EPS: RON0.099 (vs RON0.043 in 2Q 2023) Second quarter 2024 results: EPS: RON0.099 (up from RON0.043 in 2Q 2023). Revenue: RON285.0m (up 30% from 2Q 2023). Net income: RON68.9m (up 132% from 2Q 2023). Profit margin: 24% (up from 14% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 29
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to RON4.16, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 27x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 56% over the past three years. Reported Earnings • May 19
First quarter 2024 earnings released: EPS: RON0.11 (vs RON0.061 in 1Q 2023) First quarter 2024 results: EPS: RON0.11 (up from RON0.061 in 1Q 2023). Revenue: RON266.3m (up 15% from 1Q 2023). Net income: RON74.2m (up 74% from 1Q 2023). Profit margin: 28% (up from 19% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 03
Full year 2023 earnings released: EPS: RON0.27 (vs RON0.14 in FY 2022) Full year 2023 results: EPS: RON0.27 (up from RON0.14 in FY 2022). Revenue: RON945.7m (up 25% from FY 2022). Net income: RON191.1m (up 92% from FY 2022). Profit margin: 20% (up from 13% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. New Risk • Nov 17
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (5.9% average weekly change). Reported Earnings • Nov 17
Third quarter 2023 earnings released: EPS: RON0.074 (vs RON0.003 in 3Q 2022) Third quarter 2023 results: EPS: RON0.074 (up from RON0.003 in 3Q 2022). Revenue: RON233.9m (up 33% from 3Q 2022). Net income: RON51.5m (up RON49.7m from 3Q 2022). Profit margin: 22% (up from 1.0% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Nov 15
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to RON2.78, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Negligible returns to shareholders over past three years. Reported Earnings • Sep 03
Second quarter 2023 earnings released: EPS: RON0.043 (vs RON0.038 in 2Q 2022) Second quarter 2023 results: EPS: RON0.043 (up from RON0.038 in 2Q 2022). Revenue: RON219.9m (up 14% from 2Q 2022). Net income: RON29.6m (up 11% from 2Q 2022). Profit margin: 14% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. New Risk • Aug 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (5.3% average weekly change). New Risk • Jun 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (5.4% average weekly change). Reported Earnings • May 18
First quarter 2023 earnings released: EPS: RON0.061 (vs RON0.007 in 1Q 2022) First quarter 2023 results: EPS: RON0.061 (up from RON0.007 in 1Q 2022). Revenue: RON230.7m (up 36% from 1Q 2022). Net income: RON42.7m (up RON37.8m from 1Q 2022). Profit margin: 19% (up from 2.9% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 31
Full year 2022 earnings released: EPS: RON0.14 (vs RON0.15 in FY 2021) Full year 2022 results: EPS: RON0.14 (down from RON0.15 in FY 2021). Revenue: RON759.6m (up 6.9% from FY 2021). Net income: RON99.5m (down 5.9% from FY 2021). Profit margin: 13% (down from 15% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 18
Third quarter 2022 earnings released: EPS: RON0.003 (vs RON0.02 in 3Q 2021) Third quarter 2022 results: EPS: RON0.003 (down from RON0.02 in 3Q 2021). Revenue: RON175.4m (up 1.5% from 3Q 2021). Net income: RON1.83m (down 87% from 3Q 2021). Profit margin: 1.0% (down from 8.0% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Francois Marchand was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 06
Second quarter 2022 earnings released: EPS: RON0.038 (vs RON0.016 in 2Q 2021) Second quarter 2022 results: EPS: RON0.038 (up from RON0.016 in 2Q 2021). Revenue: RON193.4m (up 16% from 2Q 2021). Net income: RON26.8m (up 145% from 2Q 2021). Profit margin: 14% (up from 6.6% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Board Change • Apr 28
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Francois Marchand was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 04
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: RON0.14 (up from RON0.094 in FY 2020). Revenue: RON694.8m (up 25% from FY 2020). Net income: RON94.7m (up 44% from FY 2020). Profit margin: 14% (up from 12% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance. Reported Earnings • Nov 18
Third quarter 2021 earnings released: EPS RON0.02 (vs RON0.017 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: RON172.7m (up 26% from 3Q 2020). Net income: RON13.8m (up 20% from 3Q 2020). Profit margin: 8.0% (down from 8.4% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance. Reported Earnings • Sep 03
Second quarter 2021 earnings released: EPS RON0.016 (vs RON0.011 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: RON167.2m (up 30% from 2Q 2020). Net income: RON11.0m (up 41% from 2Q 2020). Profit margin: 6.6% (up from 6.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance. Board Change • Jul 28
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Francois Marchand was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • May 19
First quarter 2021 earnings released: EPS RON0.034 (vs RON0.049 in 1Q 2020) The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: RON163.1m (up 6.5% from 1Q 2020). Net income: RON23.6m (down 31% from 1Q 2020). Profit margin: 14% (down from 22% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 03
Full year 2020 earnings released: EPS RON0.088 (vs RON0.082 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: RON602.3m (up 7.7% from FY 2019). Net income: RON61.3m (up 40% from FY 2019). Profit margin: 10% (up from 7.8% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Duyuru • Jan 29
Nanologica AB (publ) Signs Collaboration Agreement with Zentiva for the Use of Nlab Drug Delivery Platforms Nanologica AB (publ) announced a collaboration agreement for the use of the NLAB drug delivery platforms has been signed with Zentiva, a pharmaceutical company operating in Europe and beyond. The aim of this collaboration agreement is to simplify the contract process for future product-specific agreements. The agreement gives Zentiva the right to use the NLAB drug delivery platforms for multiple drug development projects. Project specific agreements will be signed separately under this collaboration agreement. Zentiva is a producer of high-quality and affordable medicines, serving people in Europe and beyond. The Company headquartered in Prague, Czech Republic has a network of productions sites and employs more than 4 500 employees. Is New 90 Day High Low • Jan 14
New 90-day high: RON2.98 The company is up 6.0% from its price of RON2.82 on 16 October 2020. The Romanian market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.